Controlling Severe Asthma Today and Tomorrow

Jointly provided by

     PSCM logo

Support for this activity has been made possible through educational grants from AstraZeneca, and Boehringer Ingelheim Pharmaceuticals, Inc.

Release date: 7/29/2015
Expiration date: 7/29/2016
Estimated time to complete: 30 minutes

Overview

In the Virtual Practice Staff Conference Room, learners can review interactive evidence-based presentations on factors that are critical to the successful management of patients with severe asthma, such as indicators of poorly controlled asthma, characteristics of severe asthma phenotypes, and how asthma phenotypes correlate to determining optimal treatment plans. The featured presentations are Asthma Heterogeneity and Severity and Individualizing Therapeutic Strategies for Severe Asthma. Also available is the Resource Library, which houses tools that can aid clinicians in asthma assessment, and patient management.

Faculty

Eugene R. Bleecker, MD—Program Chair
Professor and Director
Center for Genomics and Personalized Medicine Research
Wake Forest School of Medicine
Winston-Salem, North Carolina

Anne M. Fitzpatrick, PhD
Assistant Professor
Department of Pediatrics
Emory University
Atlanta, Georgia

Linda Rogers, MD
Associate Professor
Icahn School of Medicine at Mount Sinai
Clinical Director, Asthma Program
Mount Sinai – National Jewish Health Respiratory Institute
New York, New York

Target Audience

This activity has been designed to meet the educational needs of allergists, immunologists, pulmonologists, and primary care providers—including nurse practitioners and physician assistants—who will be involved in the treatment of patients with asthma.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Identify indicators of poorly controlled asthma as established by the National Asthma Education and Prevention Program (NAEPP) Expert Panel Report (EPR) 3
  • List the clinical characteristics of the various phenotypes of severe asthma
  • Identify patients who have severe asthma and their respective phenotype
  • List the immune cells and cytokines involved in the pathophysiology of inflammation in asthma 
  • Outline a treatment plan to achieve and maintain control for patients with severe asthma based on phenotype

Accreditation and Credit Designation

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Penn State College of Medicine and RedMedEd. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Penn State College of Medicine designates this symposium for a maximum of 0.50 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure

Penn State College of Medicine is committed to offering CME programs that promote improvements or quality in health care and are developed free of the control of commercial interests. Reasonable efforts have been taken to ensure that our programs are balanced, independent, objective, scientific, and in compliance with regulatory requirements. Faculty, course directors, and planners have disclosed relevant financial relationships with commercial companies, and Penn State has a process in place to resolve any conflict of interest. Disclosure of a relationship is not intended to suggest or condone bias but is made to provide participants with information that might be of potential importance to their evaluation of this educational activity. Disclosures are as follows:

Eugene R. Bleecker, MD, has disclosed the following relevant financial relationships:
Consultant/Advisor: Amgen, AstraZeneca, Boehringer-Ingelheim, Forest, Genentech/Novartis/Roche, GlaxoSmithKline, MedImmune, Merck, Regeneron-Sanofi
Research Grants: AsthmaNet, SARP, Spiromics
Clinical Trials: Amgen, AstraZeneca, Boehringer-Ingelheim, Forest, Genentech/Roche, GlaxoSmithKline, Janssen/Johnson & Johnson, MedImmune, Novartis, Pfizer, Sanofi, Teva

Anne M. Fitzpatrick, PhD, has disclosed the following relevant financial relationships:
Consultant/Advisor: Genentech

Linda Rogers, MD, has disclosed the following relevant financial relationships:
Consultant/Advisor: Roche/Genentech

Planning Committee

Penn State College of Medicine staff involved in the development and review of this activity have disclosed no relevant financial relationships.

RedMedEd
Denise C. LaTemple, PhD, Director of Scientific Services, has disclosed no relevant financial relationships.
Lauren Showers, Project Manager, has disclosed no relevant financial relationships. 
Jonathan S. Simmons, ELS, Senior Managing Editor, has disclosed no relevant financial relationships.
Karen Smith, Creative Director, has disclosed no relevant financial relationships.

Unapproved Product Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Penn State College of Medicine, RedMedEd, AstraZeneca, and Boehringer Ingelheim Pharmaceuticals, Inc. do not recommend the use of any agent outside the labeled indications.

Disclaimer

The information presented in this activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician regarding diagnosis and treatment of a specific patient’s medical condition.

The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Penn State College of Medicine, RedMedEd, AstraZeneca, or Boehringer Ingelheim Pharmaceuticals, Inc. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Method of Participation

There are no fees to participate in the activity. To receive CME credit, participants must review all activity information (including the learning objectives, disclosure statements, and content) and complete the posttest and program evaluation. Certificates can be printed immediately.

For questions regarding CME credit, contact Penn State Continuing Education at (717) 531-6483 or ContinuingEd@hmc.psu.edu. Please reference activity code G5820-16-T.

Hardware/Software Requirements

  • Apple iPad or iPad mini (iOS 7 or higher) with an Internet connection
  • A computer with an Internet connection
    • Internet browser: Google Chrome, Internet Explorer 9 or higher, Firefox 26 or higher, or Safari 5 or higher
    • Additional software: Adobe Flash Player and/or an HTML 5-capable browser is required for video or audio playback; Adobe Acrobat Reader may occasionally be required

Privacy

This website is managed by RedMedEd, and their printed privacy policy applies to this site. CME credit for this activity is provided by Penn State College of Medicine. If you register for CME credit for this educational activity, RedMedEd will forward relevant personally identifiable information to Penn State College of Medicine so that we can maintain records concerning credits we issue to you. We may share aggregated data concerning registrations, post-tests, and evaluations. We will not knowingly share any personally identifiable information. Penn State College of Medicine may use the information you provide on this site to contact you about your CME credit or other relevant educational activities provided through Penn State College of Medicine. For more information, contact ContinuingEd@hmc.psu.edu.